IP Library Granted Patent US 8,007,789
Granted Patent B2
US 8,007,789 · App. 12/147,215 · Granted Aug 30, 2011

Antibiotics GE 81112 factors A, B, B1, pharmaceutically acceptable salts and compositions, and use thereof

Assignee: Vicuron Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,007,789
App. No.
12/147,215
Granted
Aug 30, 2011
Kind
B2
Abstract

The invention relates to antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 811112 factor A, factor B1 and factor B, which are produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and composition thereof, and their use as an antibacterial agent having activity versus susceptible microbes.

Claims (216)

1. Isolated antibiotic GE 81112 Factor B having the following characteristics:

A) Mass spectrum recorded from a 0.01 mg/ml solution in acetonitrile:water 50:50 giving a monoprotonated ion at 659 m/z on a Thermofinnigan LCQ deca instrument under the following electrospray conditions: Spray Voltage: 4.7 kv; Capillary temperature: 250° C.; Capillary Voltage: 9V; Infusion mode 5 μl/min.

B) Infrared spectrum ( FIG. 6 ) recorded in KBr with an IFS-48 Fourier Transform spectrophotometer showing the following main bands (cm −1 ):

3359; 2958; 2852; 2258; 2129; 1681; 1591; 1450; 1385; 1347; 1122; 1072; 1025; 998; 765

C) 1 H-NMR spectrum ( FIG. 7 ) recorded at 600 MHz at 25° C. in DMSO-d 6 and trifluoroacetic acid (drops) showing the following 1 H signals:

Chemical shift (ppm)

Multiplicity

1.52

br d

1.57-1.72

m

1.83

br d

1.90

m

2.63

dd

2.88

dd

2.92

m

3.13

br d

3.64

m

3.83

m

3.95

br d

4.35

br s

4.46

m

4.50

dd

4.60

m

5.05

d

6.46

br

6.48

s

6.93

s

7.40

br s

7.84

d

8.05

d

8.33

m

8.54

d

9.00

br d

11.72 

br s

11.75 

br s

D) 13 C-NMR spectrum ( FIG. 8 ) recorded at 150 MHz, at 25° C. in DMSO-d 6 and trifluoroacetic acid (drops) showing the following 13 C signals

13 C Chemical shift (ppm)

Multiplicity

15.9

t

27.36

t

28.40

t

35.47

t

42.87

t

50.1

d

51.20

d

56.78

d

59.73

d

64.09

d

65.14

d

66.90

d

67.77

t

110.3

d

117.85

d

122.5

s

128.4

s

139.66

s

146.7

s

156.7

s

167.4

s

170.5

s

171.3

s

171.38

s

E) Retention time 21.6 min, determined by using an analytical HPLC Shimadzu LC10-AS, equipped with an “Altima” RP18, 5 μm, 250×4.6 mm i.d column; isocratic elution performed at 1 ml/min. flow rate, with 40 mM ammonium formate buffer, brought to pH 4.5 by addition of formic acid; UV detection at 230 nm.

2. Isolated antibiotic GE 81112 factor B1 having the following characteristics:

A) Mass spectrum recorded from a 0.01 mg/ml solution in acetonitrile:water 50:50 giving a monoprotonated ion at 658 m/z ib a Termofinnigan LCQ deca instrument under the following electrospray conditions; Spray Voltage: 47 kv; Capillary Temperature: 250° C.; Capillary voltage: 9V; Infusion Mode: 5 1/min.

B) H-NMR spectrum ( FIG. 10 ) recorded at 600 MH at 25° C. in DMSO-d 6 showing the following 1 H signals:

Chemical shift (ppm)

Multiplicity

1.38

br d

1.56-1.64

m

1.76

m

2.70

m

2.82

br s

2.92

m

3.01-3.06

m

3.49

br m

3.57

br s

4.20

br dd

4.26

br

4.40

br m

4.46

m

5.05

d

5.60

br s

6.21

br

6.52

br

6.78

br s

7.13

br

7.80

br d

7.90

br d

8.44

br

C) 13 C-NMR spectrum ( FIG. 11 ) recorded at 150 Mhz, at 25° C. in DMSO-d 6 showing the following 13 C signals:

Chemical shift (ppm)

Multiplicity

17.95

t

27.97

t

29.8

t

36.54

t

43.75

t

45.65

d

50.52

d

51.9

d

57.75

d

61.0

d

64.03

d

66.7

d

66.88

d

111.07

d

118.97

d

122.47

s

127.88

s

148.08

s

159.18

s

169.44

s

171.53

s

171.81

s

173.08

s

D) Retention time 18.4 min, determined by using an analytical HPLC Shimadzu LC10-AS, equipped with an “Altima” RP18, 5 μm, 250×4.6 mm i.d column; isocratic elution performed at 1 ml/min. flow rate, with 40 mM ammonium formate buffer brought to pH 4.5 by addition of formic acid; UV detection at 230 nm.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Dec 17, 2014
From: PDL BIOPHARMA, INC.
To: VICURON PHARMACEUTICALS INC.
Reel/Frame 034527/0843 →
SECURITY AGREEMENT Recorded Oct 31, 2013
From: VICURON PHARMACEUTICALS INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 031529/0353 →
Priority Claims (1)
EP 01128204 · Nov 28, 2001 · regional
Continuity (2)
Division 10496009
Related Publication 20090023665A1 · Jan 22, 2009